{"success":true,"data":{"pressRelease":{"id":"142563","rtpr_id":"nGNX5GKJlq-20260914","ticker":"ONCO","exchange":"NASDAQ","all_tickers":["ONCO"],"title":"Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition","author":"Globe Newswire","published_at":"2026-09-14T12:30:00.455Z","article_body":"Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working\nCapital; Non-Interest Bearing Facility Is Automatically Cancelled and\nDischarged in Full Upon Closing of Pending Acquisition\n\nCINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq:\nONCO) (\"Onconetix\" or the \"Company\") today announced that it has provided a\nstrategic bridge financing facility of up to $5,000,000 to Realbotix LLC\n(\"Realbotix\"), the target of its previously announced pending acquisition, to\nsupport Realbotix's growth and working capital needs while the parties advance\ntoward closing of the acquisition. The financing was provided in connection\nwith the Share Exchange Agreement between the two companies, announced on\nFebruary 12, 2026.\n\nThe facility provides for an aggregate principal amount of up to $5,000,000,\nwith an initial advance of $2,500,000.\n\nThe facility is non-interest bearing prior to the closing of the Share\nExchange Agreement. Upon closing of the acquisition, the facility and all\nobligations thereunder will be automatically cancelled and discharged in full.\nIn addition, the cash required at closing of the acquisitions will be reduced\nby the total principal advanced under the facility plus an additional\n$500,000. If the Share Exchange Agreement is terminated, interest accrues at\n12% per annum from the date of termination. A description of the Note is\nincluded in Onconetix’s Current Report on Form 8-K filed with the SEC on\n[DATE], 2026. The full text of the Note is filed as an exhibit to that report\nand is available at www.sec.gov.\n\nAs previously announced on February 12, 2026, Onconetix entered into the Share\nExchange Agreement to acquire 100% of the issued and outstanding equity\ninterests of Realbotix LLC in an all-stock transaction. The combined company\nis expected to trade on Nasdaq following closing, which is subject to\nOnconetix shareholder approval, required regulatory approvals, and other\nclosing conditions.\n\nThis communication is being provided for informational purposes only.\nInvestors are cautioned not to place undue reliance on forward-looking or\nprojected information.\n\nAbout Onconetix, Inc.\n\nOnconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company\nfocused on the research, development, and commercialization of innovative\noncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test\nfor prostate cancer originally developed by Proteomedix and approved for sale\nin the European Union under the IVDR, which it anticipates will be marketed in\nthe U.S. as a lab developed test through its license agreement with Labcorp.\nFor more information, visit www.onconetix.com.\n\nAbout Realbotix LLC\n\nRealbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT;\nFrankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending\nacquisition. Realbotix LLC develops AI-powered humanoid robots designed for\nhuman interaction across enterprise and consumer environments. Manufactured in\nthe United States, Realbotix’s patented AI and robotics technologies enable\nlifelike expressions, motion, vision, and social engagement. For more\ninformation, visit www.realbotix.ai.\n\nAdditional Information and Where to Find It\n\nIn connection with the proposed transaction between Realbotix and Onconetix,\nOnconetix intends to file with the SEC a Registration Statement on Form S-4\n(the “Registration Statement”) to register the common stock to be issued\nby Onconetix in connection with the proposed transaction. The Registration\nStatement will include a proxy statement of Onconetix and a prospectus of\nOnconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and\nOnconetix may file with the SEC other relevant documents concerning the\nproposed transaction. After the Registration Statement is declared effective,\nthe definitive Proxy Statement/Prospectus will be sent to the stockholders of\nOnconetix to seek their approval of the proposed transaction. This is not a\nsubstitute for the Registration Statement, the Proxy Statement/Prospectus or\nany other relevant documents that Realbotix or Onconetix has filed or will\nfile with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS\nAND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE\nREGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED\nTRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR\nSUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE\nTHEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE\nPROPOSED TRANSACTION, AND RELATED MATTERS.\n\nA copy of the Registration Statement, Proxy Statement/Prospectus, as well as\nother relevant documents filed by Realbotix and Onconetix with the SEC, may be\nobtained free of charge, when they become available, at the SEC’s website at\nwww.sec.gov. The information on Realbotix or Onconetix’s respective websites\nis not, and shall not be deemed to be, a part of this communication or\nincorporated into other filings either company makes with the SEC.\n\nParticipants in the Solicitation\n\nRealbotix, Onconetix and certain of their respective directors, executive\nofficers, and employees may be deemed to be participants in the solicitation\nof proxies in connection with the proposed transaction. Information about the\ndirectors and executive officers of Onconetix, their ownership of Onconetix\ncommon stock, and Onconetix’s transactions with related persons is set forth\nin the 10-K, as filed with the SEC on March 13, 2026, and other documents that\nmay be filed from time to time with the SEC. Additional information about the\ndirectors and executive officers of Realbotix and Onconetix and other persons\nwho may be deemed to be participants in the solicitation of stockholders of\nOnconetix in connection with the proposed transaction and a description of\ntheir direct and indirect interests will be included in the Proxy\nStatement/Prospectus related to the proposed transaction or other relevant\nmaterials, which will be filed with the SEC. These documents may be obtained\nfree of charge, when they become available, at the SEC’s website at\nwww.sec.gov and from Onconetix using the sources indicated above.\n\nNo Offer or Solicitation\n\nThis communication is for informational purposes only and is not intended to\nand does not constitute an offer to sell or the solicitation of an offer to\nbuy or sell any securities or the solicitation of any proxy, vote or approval,\nnor shall there be any sale of securities in any jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to registration or\nqualification under the securities laws of any such jurisdiction. No offer of\nsecurities shall be made except by means of a prospectus meeting the\nrequirements of Section 10 of the Securities Act, or in a transaction exempt\nfrom the registration requirements of the Securities Act.\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking within the\nmeaning of the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified by the use of forward-looking words such as\n“anticipate,” “believe,” “forecast,” “estimate,” “expect,”\nand “intend,” among others. These forward-looking statements (including,\nwithout limitation, the anticipated benefits and opportunities that may be\ngenerated by the proposed transaction described herein) are based on\nOnconetix’s current expectations and actual results could differ materially.\nThere are a number of factors that could cause actual events to differ\nmaterially from those indicated by such forward-looking statements. These\nfactors include, but are not limited to, the occurrence of any event, change,\nor other circumstances that could give rise to the right of one or both of the\nparties to terminate the share exchange agreement; the possibility that the\nproposed transaction does not close when expected or at all because the\nconditions to closing are not satisfied on a timely basis or at all, including\nthe failure to timely obtain stockholder approval for the proposed transaction\nfrom Onconetix’s stockholders, if at all; risks related to Onconetix’s\ncontinued listing on Nasdaq until closing of the proposed transaction; the\noutcome of any legal proceedings that may be instituted against Realbotix,\nOnconetix, or the combined company; the possibility that the anticipated\nbenefits of the proposed transaction are not realized when expected or at all;\nthe possibility that the vision, goals, and trajectory of the combined company\nare not timely achieved or realized or achieved or realized at all; the\npossibility that the proposed transaction may be more expensive or take longer\nto complete than anticipated, including as a result of unexpected factors or\nevents; the diversion of management’s attention from ongoing business\noperations and opportunities; changes in Onconetix’s stock price before\nclosing; and other factors that may affect future results of Realbotix,\nOnconetix, or the combined company. Onconetix does not undertake an obligation\nto update or revise any forward-looking statement. Investors should read the\nrisk factors set forth in Onconetix’s Annual Report on Form 10-K filed with\nthe SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the\nSEC on or after the date thereof. All of Onconetix’s forward-looking\nstatements are expressly qualified by all such risk factors and other\ncautionary statements. The information set forth herein speaks only as of the\ndate thereof.\n\nInvestor and Media Contact:\nOnconetix, Inc.\n201 E. Fifth Street, Suite 1900\nCincinnati, OH 45202\nPhone: (513) 620-4101\nEmail: investors@onconetix.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4824d51d-2ecb-4f49-8b75-fe9b920e7b1c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5GKJlq-20260914","title":"Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition","author":"Globe Newswire","ticker":"ONCO","created":"2026-09-14T12:30:00.455Z","tickers":["ONCO"],"exchange":"NASDAQ","article_body":"Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working\nCapital; Non-Interest Bearing Facility Is Automatically Cancelled and\nDischarged in Full Upon Closing of Pending Acquisition\n\nCINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq:\nONCO) (\"Onconetix\" or the \"Company\") today announced that it has provided a\nstrategic bridge financing facility of up to $5,000,000 to Realbotix LLC\n(\"Realbotix\"), the target of its previously announced pending acquisition, to\nsupport Realbotix's growth and working capital needs while the parties advance\ntoward closing of the acquisition. The financing was provided in connection\nwith the Share Exchange Agreement between the two companies, announced on\nFebruary 12, 2026.\n\nThe facility provides for an aggregate principal amount of up to $5,000,000,\nwith an initial advance of $2,500,000.\n\nThe facility is non-interest bearing prior to the closing of the Share\nExchange Agreement. Upon closing of the acquisition, the facility and all\nobligations thereunder will be automatically cancelled and discharged in full.\nIn addition, the cash required at closing of the acquisitions will be reduced\nby the total principal advanced under the facility plus an additional\n$500,000. If the Share Exchange Agreement is terminated, interest accrues at\n12% per annum from the date of termination. A description of the Note is\nincluded in Onconetix’s Current Report on Form 8-K filed with the SEC on\n[DATE], 2026. The full text of the Note is filed as an exhibit to that report\nand is available at www.sec.gov.\n\nAs previously announced on February 12, 2026, Onconetix entered into the Share\nExchange Agreement to acquire 100% of the issued and outstanding equity\ninterests of Realbotix LLC in an all-stock transaction. The combined company\nis expected to trade on Nasdaq following closing, which is subject to\nOnconetix shareholder approval, required regulatory approvals, and other\nclosing conditions.\n\nThis communication is being provided for informational purposes only.\nInvestors are cautioned not to place undue reliance on forward-looking or\nprojected information.\n\nAbout Onconetix, Inc.\n\nOnconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company\nfocused on the research, development, and commercialization of innovative\noncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test\nfor prostate cancer originally developed by Proteomedix and approved for sale\nin the European Union under the IVDR, which it anticipates will be marketed in\nthe U.S. as a lab developed test through its license agreement with Labcorp.\nFor more information, visit www.onconetix.com.\n\nAbout Realbotix LLC\n\nRealbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT;\nFrankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending\nacquisition. Realbotix LLC develops AI-powered humanoid robots designed for\nhuman interaction across enterprise and consumer environments. Manufactured in\nthe United States, Realbotix’s patented AI and robotics technologies enable\nlifelike expressions, motion, vision, and social engagement. For more\ninformation, visit www.realbotix.ai.\n\nAdditional Information and Where to Find It\n\nIn connection with the proposed transaction between Realbotix and Onconetix,\nOnconetix intends to file with the SEC a Registration Statement on Form S-4\n(the “Registration Statement”) to register the common stock to be issued\nby Onconetix in connection with the proposed transaction. The Registration\nStatement will include a proxy statement of Onconetix and a prospectus of\nOnconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and\nOnconetix may file with the SEC other relevant documents concerning the\nproposed transaction. After the Registration Statement is declared effective,\nthe definitive Proxy Statement/Prospectus will be sent to the stockholders of\nOnconetix to seek their approval of the proposed transaction. This is not a\nsubstitute for the Registration Statement, the Proxy Statement/Prospectus or\nany other relevant documents that Realbotix or Onconetix has filed or will\nfile with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS\nAND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE\nREGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED\nTRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR\nSUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE\nTHEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE\nPROPOSED TRANSACTION, AND RELATED MATTERS.\n\nA copy of the Registration Statement, Proxy Statement/Prospectus, as well as\nother relevant documents filed by Realbotix and Onconetix with the SEC, may be\nobtained free of charge, when they become available, at the SEC’s website at\nwww.sec.gov. The information on Realbotix or Onconetix’s respective websites\nis not, and shall not be deemed to be, a part of this communication or\nincorporated into other filings either company makes with the SEC.\n\nParticipants in the Solicitation\n\nRealbotix, Onconetix and certain of their respective directors, executive\nofficers, and employees may be deemed to be participants in the solicitation\nof proxies in connection with the proposed transaction. Information about the\ndirectors and executive officers of Onconetix, their ownership of Onconetix\ncommon stock, and Onconetix’s transactions with related persons is set forth\nin the 10-K, as filed with the SEC on March 13, 2026, and other documents that\nmay be filed from time to time with the SEC. Additional information about the\ndirectors and executive officers of Realbotix and Onconetix and other persons\nwho may be deemed to be participants in the solicitation of stockholders of\nOnconetix in connection with the proposed transaction and a description of\ntheir direct and indirect interests will be included in the Proxy\nStatement/Prospectus related to the proposed transaction or other relevant\nmaterials, which will be filed with the SEC. These documents may be obtained\nfree of charge, when they become available, at the SEC’s website at\nwww.sec.gov and from Onconetix using the sources indicated above.\n\nNo Offer or Solicitation\n\nThis communication is for informational purposes only and is not intended to\nand does not constitute an offer to sell or the solicitation of an offer to\nbuy or sell any securities or the solicitation of any proxy, vote or approval,\nnor shall there be any sale of securities in any jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to registration or\nqualification under the securities laws of any such jurisdiction. No offer of\nsecurities shall be made except by means of a prospectus meeting the\nrequirements of Section 10 of the Securities Act, or in a transaction exempt\nfrom the registration requirements of the Securities Act.\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking within the\nmeaning of the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified by the use of forward-looking words such as\n“anticipate,” “believe,” “forecast,” “estimate,” “expect,”\nand “intend,” among others. These forward-looking statements (including,\nwithout limitation, the anticipated benefits and opportunities that may be\ngenerated by the proposed transaction described herein) are based on\nOnconetix’s current expectations and actual results could differ materially.\nThere are a number of factors that could cause actual events to differ\nmaterially from those indicated by such forward-looking statements. These\nfactors include, but are not limited to, the occurrence of any event, change,\nor other circumstances that could give rise to the right of one or both of the\nparties to terminate the share exchange agreement; the possibility that the\nproposed transaction does not close when expected or at all because the\nconditions to closing are not satisfied on a timely basis or at all, including\nthe failure to timely obtain stockholder approval for the proposed transaction\nfrom Onconetix’s stockholders, if at all; risks related to Onconetix’s\ncontinued listing on Nasdaq until closing of the proposed transaction; the\noutcome of any legal proceedings that may be instituted against Realbotix,\nOnconetix, or the combined company; the possibility that the anticipated\nbenefits of the proposed transaction are not realized when expected or at all;\nthe possibility that the vision, goals, and trajectory of the combined company\nare not timely achieved or realized or achieved or realized at all; the\npossibility that the proposed transaction may be more expensive or take longer\nto complete than anticipated, including as a result of unexpected factors or\nevents; the diversion of management’s attention from ongoing business\noperations and opportunities; changes in Onconetix’s stock price before\nclosing; and other factors that may affect future results of Realbotix,\nOnconetix, or the combined company. Onconetix does not undertake an obligation\nto update or revise any forward-looking statement. Investors should read the\nrisk factors set forth in Onconetix’s Annual Report on Form 10-K filed with\nthe SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the\nSEC on or after the date thereof. All of Onconetix’s forward-looking\nstatements are expressly qualified by all such risk factors and other\ncautionary statements. The information set forth herein speaks only as of the\ndate thereof.\n\nInvestor and Media Contact:\nOnconetix, Inc.\n201 E. Fifth Street, Suite 1900\nCincinnati, OH 45202\nPhone: (513) 620-4101\nEmail: investors@onconetix.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4824d51d-2ecb-4f49-8b75-fe9b920e7b1c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-14T12:30:00.494618572Z","server_sent_at_ms":1789389000494},"received_at":"2026-09-14T12:30:00.584Z","source_url":null},"analysis":{"id":"131399","press_release_id":"142563","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Onconetix is funding its acquisition target pre-close; if the deal terminates, repayment depends on Realbotix's financial condition (only 12% interest protection)","All-stock acquisition will dilute existing ONCO shareholders; exchange ratio and implied deal value not disclosed in this release","Closing still subject to Onconetix shareholder approval and regulatory approvals — deal-completion risk","Press release contains an unfilled '[DATE]' placeholder in the Form 8-K filing reference — disclosure quality lapse"],"eventType":"debt_offering","narrative":"Onconetix has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC, the target of its pending acquisition, with an initial advance of $2,500,000 to support Realbotix's growth and working capital ahead of closing.\n\nThe facility is non-interest bearing prior to closing, and upon completion of the Share Exchange Agreement it and all obligations will be automatically cancelled and discharged in full. Cash required at closing will be reduced by the total principal advanced plus an additional $500,000.\n\nIf the Share Exchange Agreement is terminated, interest accrues at 12% per annum from the termination date, giving Onconetix downside protection if the deal fails.\n\nThe underlying all-stock acquisition of 100% of Realbotix was announced on February 12, 2026, and closing remains subject to Onconetix shareholder approval, regulatory approvals, and other closing conditions.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Bridge financing signals the Realbotix acquisition is advancing toward closing, but micro-cap ONCO is now carrying pre-close credit exposure to its own target."},"keyFigures":{"customDimensions":{"initial_advance":2500000,"bridge_facility_total":5000000,"termination_interest_rate":"12% per annum","closing_cash_reduction_extra":500000}},"quotedText":"","namedEntities":{"people":[],"products":["Proclarix","AI-powered humanoid robots"],"companies":[{"name":"Onconetix, Inc.","ticker":"ONCO","relationship":"filer/acquirer/lender"},{"name":"Realbotix LLC","relationship":"acquisition target and borrower"},{"name":"Realbotix Corp.","ticker":"XBOT","relationship":"parent company of acquisition target (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF)"},{"name":"Labcorp","relationship":"license agreement partner for U.S. marketing of Proclarix"},{"name":"Proteomedix","relationship":"original developer of Proclarix"}],"dollarAmounts":[{"amount":"$5,000,000","context":"aggregate principal amount of bridge financing facility"},{"amount":"$2,500,000","context":"initial advance under the bridge facility"},{"amount":"$500,000","context":"additional reduction in cash required at closing, on top of principal advanced"}]},"materialImpact":{"score":2,"reasoning":"Ancillary bridge financing (up to $5.0M facility, $2.5M initially advanced) supporting a previously announced all-stock acquisition; deal economics are essentially unchanged since the facility is cancelled at closing and merely reduces closing cash. The M&A itself was disclosed in February 2026, so this is a procedural financing update, not a new market-moving announcement."},"tickerRelevance":{"others":[{"ticker":"XBOT","relevance":"parent company of acquisition target (TSX-V listing)"},{"ticker":"XBOTF","relevance":"OTC listing of Realbotix Corp., parent of acquisition target"},{"ticker":"76M0.F","relevance":"Frankfurt listing of Realbotix Corp., parent of acquisition target"}],"primary":"ONCO"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":["m_and_a"],"importanceComponents":{"dealStatus":"pending — shareholder and regulatory approvals outstanding","tickerTier":"micro-cap biotech","eventGravity":"ancillary bridge financing for previously announced pending acquisition","facilitySize":"up to $5M facility; $2.5M initial advance","retailThemeBoost":"AI humanoid robots target theme adds niche retail interest despite small-cap filer"}},"event_type":"debt_offering","event_type_secondary":["m_and_a"],"sentiment":"neutral","material_impact_score":2,"narrative":"Onconetix has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC, the target of its pending acquisition, with an initial advance of $2,500,000 to support Realbotix's growth and working capital ahead of closing.\n\nThe facility is non-interest bearing prior to closing, and upon completion of the Share Exchange Agreement it and all obligations will be automatically cancelled and discharged in full. Cash required at closing will be reduced by the total principal advanced plus an additional $500,000.\n\nIf the Share Exchange Agreement is terminated, interest accrues at 12% per annum from the termination date, giving Onconetix downside protection if the deal fails.\n\nThe underlying all-stock acquisition of 100% of Realbotix was announced on February 12, 2026, and closing remains subject to Onconetix shareholder approval, regulatory approvals, and other closing conditions.","key_figures":{"customDimensions":{"initial_advance":2500000,"bridge_facility_total":5000000,"termination_interest_rate":"12% per annum","closing_cash_reduction_extra":500000}},"named_entities":{"people":[],"products":["Proclarix","AI-powered humanoid robots"],"companies":[{"name":"Onconetix, Inc.","ticker":"ONCO","relationship":"filer/acquirer/lender"},{"name":"Realbotix LLC","relationship":"acquisition target and borrower"},{"name":"Realbotix Corp.","ticker":"XBOT","relationship":"parent company of acquisition target (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF)"},{"name":"Labcorp","relationship":"license agreement partner for U.S. marketing of Proclarix"},{"name":"Proteomedix","relationship":"original developer of Proclarix"}],"dollarAmounts":[{"amount":"$5,000,000","context":"aggregate principal amount of bridge financing facility"},{"amount":"$2,500,000","context":"initial advance under the bridge facility"},{"amount":"$500,000","context":"additional reduction in cash required at closing, on top of principal advanced"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T12:31:16.738Z","global_importance":22,"audience_relevance":25,"importance_components":{"dealStatus":"pending — shareholder and regulatory approvals outstanding","tickerTier":"micro-cap biotech","eventGravity":"ancillary bridge financing for previously announced pending acquisition","facilitySize":"up to $5M facility; $2.5M initial advance","retailThemeBoost":"AI humanoid robots target theme adds niche retail interest despite small-cap filer"}},"durationMs":44225,"modelName":"glm-5.3-flash"}}